Price targets

Analyst ratings

4 analysts rated this company in the past 90 days. The average target price is €26.00, this is a change of +7.3% compared to the current price.

• September 24, 2025

  Jefferies maintains Philips on 'Hold' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Hold" rating on Philips with a price target of €25. After a reassuring second quarter, the medical technology company expects further improvement in the third quarter, Julien Dormois wrote in an outlook released Wednesday for the interim report on November 4. He anticipates organic sales growth above the annual target. Margins are likely to be higher than in the first half of the year, but not increase year-on-year. The stock's valuation appears fair./gl/men

  Publication of the original study: September 24, 2025 / 12:30 PM / ET First distribution of the original study: September 24, 2025 / 12:30 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 30, 2025

  Deutsche Bank Research maintains Philips' 'Hold' rating - target €23

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for Philips with a price target of €23. The medical technology manufacturer exceeded expectations and slightly raised its margin forecast due to lower tariff burdens, Falko Friedrichs wrote on Wednesday after the quarterly results. Consensus estimates are expected to rise slightly./ajx/mis

  Publication of the original study: July 30, 2025 / Time not specified in study / CET. First distribution of the original study: July 30, 2025 / 8:08 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 29, 2025

  UBS raises target for Philips to 28 euros - 'Buy'

  ZURICH (dpa-AFX Analyst) - The Swiss major bank UBS has raised its price target for Philips from 26 to 28 euros following quarterly figures and left the rating at "Buy". Even if the results alone do not signal a turnaround for the medical technology group, they are further evidence that costs are under control and new products will now lead to faster order backlog growth and soon also to higher revenue, Graham Doyle wrote in a study released Wednesday./edh/nas

  Publication of the original study: July 29, 2025 / 11:21 PM / GMT

  First distribution of the original study: July 29, 2025 / 11:21 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 29, 2025

  Jefferies raises target for Philips to 25 euros - 'Hold'

  NEW YORK (dpa-AFX Analyst) - Following second-quarter results, analyst Jefferies raised its price target for Philips from €22 to €25 and maintained its "Hold" rating. The medical technology manufacturer clearly exceeded expectations, wrote Julien Dormois in a study released Tuesday. Order intake was surprisingly good, and the company appears to have overcome the worst.

  Publication of the original study: July 29, 2025 / 2:59 p.m. / ET. First distribution of the original study: July 29, 2025 / 2:59 p.m. / ET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 29, 2025

  UBS maintains Philips 'Buy' - target 26 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Philips following its quarterly results, with a price target of €26. Adjusted operating profit (EBITA) exceeded the consensus estimate by a whopping 26 percent, Graham Doyle wrote in an initial reaction released Tuesday. The medical technology group's revenue was slightly higher than expected./rob/edh/la

  Publication of the original study: July 29, 2025 / 5:43 a.m. / GMT

  First distribution of the original study: July 29, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 29, 2025

  Jefferies maintains Philips on 'Hold' - target 22 euros

  NEW YORK (dpa-AFX Analyst) - Following the company's earnings release, analyst Jefferies maintained its "Hold" rating for Philips with a price target of €22. Julien Dormois emphasized in a study released Tuesday that the healthcare technology manufacturer clearly exceeded expectations in the second quarter. On a comparable basis, sales increased, while consensus had expected a decline. On the margin side, a similar picture emerges when comparing expectations./tih/nas

  Publication of the original study: July 29, 2025 / 2:03 a.m. / ET

  First distribution of the original study: July 29, 2025 / 2:03 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 18, 2025

  Jefferies maintains Philips on 'Hold' - target 22 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Hold" rating on Philips with a price target of €22. After a weak start to the year, the medical technology company has forecast an improvement for the quarterly figures due on July 29, Julien Dormois wrote in his outlook published on Friday. This is unlikely to change the risks to the targeted annual sales growth, which depends primarily on the company's future business performance. However, given the easing tensions between the US and China, there is scope for raising the margin target.

  Publication of the original study: July 18, 2025 / 12:44 PM / ET. First distribution of the original study: July 18, 2025 / 12:44 PM / ET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 7, 2025

  Jefferies maintains Philips on 'Hold' - target 22 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Hold" rating on Philips with a price target of €22. Chinese sanctions against medical devices from the EU would have only a minor impact on the European medical technology manufacturers he monitors, wrote Julien Dormois in his industry commentary published on Monday. Their products manufactured in China, as well as imported products whose EU components account for less than 50 percent of the order value, were unaffected by the Chinese measures. Companies such as Elekta, Philips, and Siemens Healthineers have significant production capacity in China. Philips itself has stated that the direct impact is likely limited./gl/ag

  Publication of the original study: July 7, 2025 / 7:41 a.m. / ET First distribution of the original study: July 7, 2025 / 7:41 a.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• July 6, 2025

  UBS maintains Philips 'Buy' - target 26 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Philips at "Buy" with a price target of €26. The second quarter is likely to bring a turnaround in earnings performance and sentiment, wrote Graham Doyle in his outlook on the Dutch company's interim report, published on Monday./rob/ag/gl

  Publication of the original study: July 6, 2025 / 10:04 p.m. / GMT First distribution of the original study: July 7, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• June 19, 2025

  UBS maintains Philips 'Buy' - target 26 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Philips with a price target of €26. The Dutch company is the company in the European medtech sector where investors are particularly unanimous in expecting a lower sales forecast with the quarterly report, Graham Doyle wrote in his commentary released Friday following recent discussions. Aside from the favorable valuation, no positive comment has been made about the shares./ag/jha/

  Publication of the original study: June 19, 2025 / 2:30 p.m. / GMT

  First distribution of the original study: June 20, 2025 / Time not specified in the study / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 12, 2025

  Deutsche Bank lowers Philips target to 23 euros - 'Hold'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has lowered its price target for Philips from €26 to €23, but maintained its "Hold" rating. Following the recent profit warning due to the customs issue, Falko Friedrichs remains cautious regarding the medical technology group's investment background, wrote in a study released Monday./edh/ck

  Publication of the original study: May 12, 2025 / Time not specified in study / CEST

  First distribution of the original study: May 12, 2025 / 8:07 a.m. / CEST

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 7, 2025

  Goldman lowers Philips target to 28 euros - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Philips from €32 to €28, but maintained its "Buy" rating. Richard Felton adjusted his estimates Wednesday evening to reflect the quarterly results and tariff headwinds./ag/ajx

  Publication of the original study: May 7, 2025 / 9:14 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 6, 2025

  Jefferies lowers target for Philips to 22 euros - 'Hold'

  NEW YORK (dpa-AFX Analyst) - Following its quarterly results, analyst Jefferies lowered its price target for Philips from €25 to €22 and maintained its "Hold" rating. The medical technology company had a slow start to the year, Julien Dormois wrote in a study released Tuesday. Due to the tariff conflict, he has reduced his profit forecasts for 2025 and 2026./edh/he

  Publication of the original study: May 6, 2025 / 3:12 PM / ET First distribution of the original study: May 6, 2025 / 3:12 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 6, 2025

  Jefferies maintains Philips on 'Hold' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Hold" rating for Philips with a price target of €25. The first quarter slightly exceeded expectations, Julien Dormois wrote on Tuesday after the interim report. However, the overall start to the year was sluggish. Dormois considers the valuation fair given the clear focus on the second half of the year.

  Publication of the original study: May 6, 2025 / 2:02 AM / ET. First distribution of the original study: May 6, 2025 / 2:02 AM / ET.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• May 6, 2025

  UBS maintains Philips 'Buy' - target 29 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Philips with a price target of €29. The Dutch company's shares are likely to react negatively to the quarterly report, Graham Doyle wrote on Tuesday. Although the results were good, the reduction in the margin target was more significant than expected./rob/ag/gl

  Publication of the original study: May 6, 2025 / 5:23 a.m. / GMT First distribution of the original study: May 6, 2025 / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 15, 2025

  UBS maintains Philips 'Buy' - target 29 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Philips with a price target of €29. Analyst Graham Doyle wrote in his commentary on the medical technology sector published Wednesday that GE Healthcare, Philips, and Siemens Healthineers are at the greatest risk of further tariff headwinds. He expects GE Healthcare to be the most exposed to tariff headwinds./ag/bek

  Publication of the original study: April 15, 2025 / 5:21 p.m. / GMT

  First distribution of the original study: April 16, 2025 / Time not specified in study / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• April 1, 2025

  Goldman lowers target for Philips to 32 euros - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Philips from €33 to €32, but maintained its "Buy" rating. The first-quarter figures, expected on May 6, are likely to demonstrate a more significant organic sales decline for the medical technology company than the market expected, analyst Richard Felton wrote in an outlook released Wednesday. However, he still sees room for improvement over the course of the year. The stock also remains attractively valued./gl/tav

  Publication of the original study: April 1, 2025 / 9:24 PM / BST First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 24, 2025

  Jefferies maintains Philips on 'Hold' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Hold" rating for Philips ahead of first-quarter results, with a price target of €25. As the medical technology manufacturer has signaled, a slow start to the year is expected, analyst Julien Dormois wrote in his outlook on Tuesday. Revenue and profitability are likely to have declined./bek/ag

  Publication of the original study: March 24, 2025 / 5:36 PM / ET

  First distribution of the original study: March 24, 2025 / 8:01 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 4, 2025

  UBS maintains Philips 'Buy' - target 29 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Philips at "Buy" after a meeting with CFO Charlotte Hanneman, with a price target of €29. The statements regarding the individual sales regions underpin the company's outlook for the current year, analyst Graham Doyle wrote on Tuesday evening. There is unlikely to be any improvement in the consumer-related medical technology business in China, but hospital investments in the US are likely to continue to develop well./bek/ag

  Publication of the original study: March 4, 2025 / 7:12 PM / GMT

  First distribution of the original study: March 4, 2025 / 7:12 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• March 4, 2025

  UBS maintains Philips 'Buy' - target 29 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Philips with a price target of €29 following an in-house industry conference. The regional business outlook, which underpins the outlook for the current fiscal year, remained largely unchanged, analyst Graham Doyle wrote in a report released Tuesday. The medical technology group's highest priority is reducing the gap between reported and adjusted earnings./la/ngu

  Publication of the original study: March 4, 2025 / 7:12 PM / GMT First distribution of the original study: March 4, 2025 / 7:12 PM / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 26, 2025

  Bernstein maintains Philips' 'Outperform' rating - target 32 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Philips at "Outperform" with a price target of €32. Following the share price crash on February 19, when the medical technology manufacturer presented its quarterly results, analyst Lisa Bedell Clive wrote that she has now considered the company's exposure to China and its share price performance relative to its industry peers. She remains confident about the company's long-term prospects, she concluded in the study released Thursday. In addition, the stock is not expensive./ck/gl

  Publication of the original study: February 26, 2025 / 10:19 PM / UTC. First distribution of the original study: February 27, 2025 / 5:00 AM / UTC.

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 21, 2025

  UBS maintains Philips 'Buy' - target 29 euros

  ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Philips with a price target of €29. A meeting with the Dutch company's management answered important questions, analyst Graham Doyle wrote on Friday morning following this week's annual report. His assessment that the outlook for the first quarter was too cautious was confirmed. CEO Roy Jakobs also explained why a business recovery – especially in the personal health sector in China – is virtually guaranteed in the second half of the year./ag

  Publication of the original study: February 21, 2025 / 8:45 a.m. / GMT

  First distribution of the original study: February 21, 2025 / 8:45 a.m. / GMT

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 20, 2025

  Deutsche Bank Research maintains Philips at 'Hold' - target 26 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for Philips following its quarterly results, with a price target of €26. The medical technology group's results were in line with consensus estimates, wrote analyst Falko Friedrichs in a commentary published Thursday./edh/gl

  Publication of the original study: February 20, 2025 / Time not specified in study / CET First distribution of the original study: February 20, 2025 / 7:48 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 19, 2025

  Jefferies maintains Philips on 'Hold' - target 25 euros

  NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Hold" rating for Philips with a price target of €25. The cautious outlook has overshadowed the company, analyst Julien Dormois wrote on Wednesday after the medical technology manufacturer's quarterly results. China is still a burden./ajx/he

  Publication of the original study: February 19, 2025 / 1:30 p.m. / ET First distribution of the original study: February 19, 2025 / 1:30 p.m. / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 19, 2025

  Bernstein maintains Philips' 'Outperform' rating - target 32 euros

  NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Philips at "Outperform" with a price target of €32. The medical technology group's results slightly missed market expectations, analyst Lisa Bedell Clive wrote on Wednesday after the quarterly report. The upper end of the annual targets is in line with the consensus./ag/la

  Publication of the original study: February 19, 2025 / 7:28 a.m. / UTC

  First distribution of the original study: February 19, 2025 / 7:28 a.m. / UTC

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• February 19, 2025

  Goldman maintains Philips 'Buy' - target 33 euros

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Philips with a price target of €33. Overall, expectations were largely met, analyst Richard Felton wrote on Wednesday after the quarterly results. The targets for 2025 are somewhat weaker, although a conservative outlook was to be expected./ag/edh

  Publication of the original study: February 19, 2025 / 7:43 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• January 10, 2025

  Goldman raises target for Philips to 33 euros - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Philips from €32 to €33 and maintained its "Buy" rating. Analyst Richard Felton wrote in a report released Friday that he sees further room for improvement in both consensus estimates and the company's valuation. Since he began monitoring the stock in July 2023, the medical technology group has regularly exceeded expectations and raised its targets – except for the third quarter of 2024. The subsequently revised outlook for 2024 is prudent and now contains hardly any risks./gl/la

  Publication of the original study: January 10, 2025 / 5:00 a.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 29, 2024

  Jefferies maintains Philips on 'Hold' - target 25 euros

  NEW YORK (dpa-AFX Analyser) - The analysis house Jefferies has maintained its rating for Philips at "Hold" with a price target of 25 euros. In a study published Friday, analyst Julien Dormois referred to his recent upgrade of the healthcare technology manufacturer, following which he now also extended his vote for the US-traded depositary receipts./tih/he

  Publication of the original study: November 29, 2024 / 12:55 PM / ET First distribution of the original study: November 29, 2024 / 1:01 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• November 1, 2024

  Goldman lowers target for Philips to 32 euros - 'Buy'

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has lowered its price target for Philips from €35 to €32. However, the rating was maintained at "Buy," and the shares also remain on the "Conviction Buy List" for particularly promising stocks. Despite the weakness in China, analyst Richard Felton continues to see compelling reasons to buy the medical technology company's shares, as he wrote in his commentary on Friday evening, despite the recent disappointing quarterly figures. While it is difficult to predict when these headwinds will subside, the forecast for fiscal year 2024 should now no longer be too risky. Philips continues to make progress with innovations that should increase growth, margins, and free cash flow./ck/ag

  Publication of the original study: November 1, 2024 / 7:31 PM / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 30, 2024

  Deutsche Bank Research lowers target for Philips - 'Hold'

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research lowered its price target for Philips from €27 to €25, but maintained its "Hold" rating. The continued slowdown in China is causing pressure, wrote analyst Falko Friedrichs in his commentary on the latest quarterly figures released Wednesday./ag/nas

  Publication of the original study: October 30, 2024 / Time not specified in study / CET

  First distribution of the original study: October 30, 2024 / 08:17 / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 29, 2024

  Deutsche Bank Research maintains Philips 'Hold' - Target 27 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Philips at "Hold" with a price target of €27 following its third-quarter results. The medical technology company presented mixed results, wrote analyst Falko Friedrichs in a report published Tuesday. The outlook was also lowered due to China's weakness./mis/zb

  Publication of the original study: October 29, 2024 / Time not specified in the study / CET

  First distribution of the original study: October 29, 2024 / 8:00 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 28, 2024

  Jefferies upgrades Philips to 'Hold' - target raised to 25 euros

  NEW YORK (dpa-AFX Analyst) - The research firm Jefferies has upgraded Philips from "underperform" to "hold" and raised its price target from €23.50 to €25. The valuation has collapsed due to concerns about the company's business in China, analyst Julien Dormois wrote on Monday after the share price slump following the lowered sales forecast and the even weaker-than-expected quarter. Opportunities and risks are now more balanced at the current price level./ag/ajx

  Publication of the original study: October 28, 2024 / 5:01 PM / ET

  First distribution of the original study: October 28, 2024 / 8:00 PM / ET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 28, 2024

  Goldman maintains Philips 'Buy' rating - target 35 euros

  NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its "Buy" rating for Philips with a price target of €35. The Dutch company presented weak results, analyst Richard Felton wrote on Monday morning. Annual targets were lowered due to China./ag/ajx

  Publication of the original study: October 28, 2024 / 7:21 a.m. / GMT

  First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

• October 4, 2024

  Deutsche Bank Research maintains Philips 'Hold' - Target 27 euros

  FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Philips at "Hold" with a price target of €27. The medical technology group's operating result (adjusted EBITDA) is expected to have increased by 17 percent, wrote analyst Falko Friedrichs in his outlook for the quarterly report, published Friday./edh/ag

  Publication of the original study: October 4, 2024 / Time not specified in study / CET

  First distribution of the original study: October 4, 2024 / 8:05 a.m. / CET

  Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.